Posts by: Inês Martins PhD

Inês Martins PhD

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

July 30, 2020July 30, 2020

Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer

News

Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings ... Read more

July 21, 2020July 21, 2020

Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds

News

A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins — may improve the effectiveness of PARP inhibitors in ovarian cancers with mutations in DNA repair ... Read more

March 20, 2019

Removing Lymph Nodes Does Not Improve Survival Outcomes of Advanced Ovarian Cancer Patients, Trial Shows

News

Women with advanced ovarian cancer who underwent a complete resection of their tumor and have normal lymph nodes do not have better survival outcomes if the lymph nodes surrounding the tumor ... Read more

March 11, 2019

Mirvetuximab Soravtansine Fails to Delay Disease Progression in FRα-positive Ovarian Cancers, Trial Shows

News

Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in ... Read more

February 13, 2019

Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds

News

A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more

February 1, 2019

Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer

News

A combination of the investigational treatment alisertib and weekly Taxol (paclitaxel) showed promising anti-tumor activity in ovarian cancer patients treated in a Phase 1/2 trial, warranting further studies of the combination. ... Read more

January 28, 2019

Report: Imported Liposomal Doxorubicin Yields Similar Outcomes as Approved OC Formulation

News

A non-approved formulation of pegylated liposomal doxorubicin — called Lipodox — seems to lead to similar response rates and time to disease progression in ovarian cancer patients as the approved Doxil formulation, ... Read more

January 16, 2019

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

News

The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV‘s lead candidate DPX-Survivac, Incyte’s experimental epacadostat, and low-dose chemotherapy, a Phase ... Read more

January 7, 2019

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

News

Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). ... Read more